Undefined myasthenias: clinical and molecular characterisation and optimised therapy by Rodríguez Cruz, PM

Myasthenic syndromes due to defects in COL13A1 and in the N‐linked glycosylation pathway by Beeson, D, Cossins, J, Rodriguez Cruz, PM, Maxwell, S, Liu, W-W, Palace, J

Congenital myasthenic syndrome due to mutations in MUSK suggests that the level of MuSK phosphorylation is crucial for governing synaptic structure by Rodríguez Cruz, PM, Cossins, J, Cheung, J, Maxwell, S, Jayawant, S, Herbst, R, Waithe, D, Kornev, AP, Palace, J, Beeson, D

Presynaptic congenital myasthenic syndrome due to three novel mutations in SLC5A7 encoding the sodium-dependant high-affinity choline transporter by Rodríguez Cruz, PM, Hughes, I, Manzur, A, Munot, P, Ramdas, S, Wright, R, Breen, C, Pitt, M, Pagnamenta, AT, Taylor, JC, Palace, J, Beeson, D

Seasonal distribution of attacks in aquaporin-4 antibody disease and myelin-oligodendrocyte antibody disease. by Dos Passos, GR, Elsone, L, Luppe, S, Kitley, J, Messina, S, Rodríguez Cruz, PM, Harding, K, Mutch, K, Leite, MI, Robertson, N, Jacob, A, Palace, J

Serological and experimental studies in different forms of myasthenia gravis by Vincent, A, Huda, S, Cao, M, Cetin, H, Koneczny, I, Rodriguez Cruz, PM, Jacobson, L, Viegas, S, Jacob, S, Woodhall, M, Nagaishi, A, Maniaol, A, Damato, V, Leite, MI, Cossins, J, Webster, R, Palace, J, Beeson, D